Skip to main content

Table 5 HR-HPV distribution of SureX HPV and Venus HPV test results

From: Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening

HPV genotype

SureX HPV

Venus HPV

aSureX+/

SureX+/

SureX−/

SureX−/

Positive agreement (%)

Kappar

95% CI

aVenus+

Venus−

Venus+

Venus−

HPV 16

144

143

138

6

5

141

92.6

0.924

0.876–0.966

HPV18

28

32

27

1

5

257

81.8

0.889

0.786–0.970

HPV58

26

23

22

4

1

263

81.5

0.889

0.772–0.978

HPV52

18

20

17

1

3

269

81

0.887

0.758–0.976

HPV33

14

13

13

1

0

276

92.9

0.916

0.863–1.00

HPV51

10

9

9

1

0

280

90

0.946

0.775–1.00

HPV66

8

8

7

1

1

281

77.8

0.871

0.594–1.00

HPV35

4

3

3

1

0

286

75

0.855

0.329–1.00

HPV59

6

4

4

2

0

284

66.7

0.797

0.329–1.00

HPV56

7

8

6

1

2

281

66.7

0.795

0.491–1.00

HPV39

10

13

9

1

4

276

64.3

0.696

0.502–0.864

HPV45

5

3

2

3

1

284

33.3

0.493

− 0.862

HPV31

6

7

3

3

4

280

30

0.449

− 0.777

HPV68

4

3

0

4

3

283

0

− 0.012

− 0.025

  1. aSureX: SureX HPV test; Venus:Venus HPV test
  2. Single HPV subtypes and multiple HPV subtypes were calculated together